Change in spinal bone mineral density as estimated by Hounsfield units following osteoporosis treatment with romosozumab, teriparatide, denosumab, and alendronate: an analysis of 318 patients

特立帕肽 医学 德诺苏马布 骨质疏松症 霍恩斯菲尔德秤 骨矿物 内科学 泌尿科 外科 计算机断层摄影术
作者
Anthony L. Mikula,Nikita Lakomkin,Abdelrahman M. Hamouda,Megan C. Everson,Zach Pennington,Rahul Robaish Kumar,Zachariah W. Pinter,Michael L. Martini,Mohamad Bydon,Kurt A. Kennel,Francis I. Baffour,Ahmad Nassr,Brett A. Freedman,Arjun S. Sebastian,Kingsley Abode-Iyamah,Paul A. Anderson,Jeremy L. Fogelson,Benjamin D. Elder
出处
期刊:Journal of neurosurgery [Journal of Neurosurgery Publishing Group]
卷期号:: 1-7 被引量:1
标识
DOI:10.3171/2024.4.spine2424
摘要

OBJECTIVE The purpose of this study was to determine the effect of osteoporosis medications on opportunistic CT-based Hounsfield units (HU). METHODS Spine and nonspine surgery patients were retrospectively identified who had been treated with romosozumab for 3 to 12 months, teriparatide for 3 to 12 months, teriparatide for > 12 months, denosumab for > 12 months, or alendronate for > 12 months. HU were measured in the L1–4 vertebral bodies. One-way ANOVA was used to compare the mean change in HU among the five treatment regimens. RESULTS In total, 318 patients (70% women) were included, with a mean age of 69 years and mean BMI of 27 kg/m 2 . There was a significant difference in mean HU improvement (p < 0.001) following treatment with romosozumab for 3 to 12 months (n = 32), teriparatide for 3 to 12 months (n = 30), teriparatide for > 12 months (n = 44), denosumab for > 12 months (n = 123), and alendronate for > 12 months (n = 100). Treatment with romosozumab for a mean of 10.5 months significantly increased the mean HU by 26%, from a baseline of 85 to 107 (p = 0.012). Patients treated with teriparatide for > 12 months (mean 23 months) experienced a mean HU improvement of 25%, from 106 to 132 (p = 0.039). Compared with the mean baseline HU, there was no significant difference after treatment with teriparatide for 3 to 12 months (110 to 119, p = 0.48), denosumab for > 12 months (105 to 107, p = 0.68), or alendronate for > 12 months (111 to 113, p = 0.80). CONCLUSIONS Patients treated with romosozumab for a mean of 10.5 months and teriparatide for a mean of 23 months experienced improved spinal bone mineral density as estimated by CT-based opportunistic HU. Given the shorter duration of effective treatment, romosozumab may be the preferred medication for optimization of osteoporotic patients in preparation for elective spine fusion surgery.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
爆米花应助YJL采纳,获得10
刚刚
Judy完成签到 ,获得积分10
2秒前
Grinder完成签到 ,获得积分10
3秒前
3秒前
4秒前
刻苦的鸭子完成签到 ,获得积分10
4秒前
6秒前
8秒前
科研通AI2S应助欢呼老鼠采纳,获得10
9秒前
orange发布了新的文献求助10
10秒前
云染完成签到 ,获得积分10
11秒前
温暖的思柔完成签到 ,获得积分10
12秒前
junyang发布了新的文献求助10
12秒前
Orange应助Soleil采纳,获得10
14秒前
14秒前
康康关注了科研通微信公众号
15秒前
15秒前
19秒前
香蕉觅云应助武雨寒采纳,获得10
19秒前
hannibal完成签到,获得积分10
21秒前
22秒前
斯文棒球发布了新的文献求助10
22秒前
晏晏完成签到,获得积分10
23秒前
24秒前
852应助hannibal采纳,获得10
24秒前
25秒前
27秒前
27秒前
Akim应助雨佳人圭采纳,获得10
27秒前
汉堡包应助何博采纳,获得10
28秒前
Qiqinnn完成签到 ,获得积分10
28秒前
爱笑灵竹发布了新的文献求助10
28秒前
香蕉觅云应助夏冰雹采纳,获得10
29秒前
青耕完成签到 ,获得积分10
29秒前
YJL发布了新的文献求助10
30秒前
Qiqinnn关注了科研通微信公众号
33秒前
35秒前
35秒前
维生素发布了新的文献求助10
36秒前
37秒前
高分求助中
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
Retention of title in secured transactions law from a creditor's perspective: A comparative analysis of selected (non-)functional approaches 500
"Sixth plenary session of the Eighth Central Committee of the Communist Party of China" 400
New China Forges Ahead: Important Documents of the Third Session of the First National Committee of the Chinese People's Political Consultative Conference 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3056197
求助须知:如何正确求助?哪些是违规求助? 2712820
关于积分的说明 7433125
捐赠科研通 2357792
什么是DOI,文献DOI怎么找? 1249053
科研通“疑难数据库(出版商)”最低求助积分说明 606843
版权声明 596195